Moderna Announces Pricing of Initial Public Offering

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Moderna, Inc. (Nasdaq: MRNA), a clinical stage biotechnology company
pioneering messenger RNA (mRNA) therapeutics and vaccines to create a
new generation of transformative medicines for patients, today announced
the pricing of its initial public offering of 26,275,993 shares of
common stock at a public offering price of $23.00 per share, before
underwriting discounts and commissions. Moderna’s common stock is
expected to begin trading on The Nasdaq Global Select Market on December
7, 2018 under the ticker symbol “MRNA.” All of the common stock is being
offered by Moderna. The gross proceeds of the offering, before deducting
underwriting discounts and commissions and other offering expenses
payable by Moderna, are expected to be $604.3 million, excluding any
exercise of the underwriters’ option to purchase additional shares. The
offering is expected to close on December 11, 2018, subject to
satisfaction of customary closing conditions. Moderna has granted the
underwriters a 30-day option to purchase up to an additional 3,941,398
shares of Moderna’s common stock at the initial public offering price,
less underwriting discounts and commissions.

Morgan Stanley, Goldman Sachs & Co. LLC and J.P. Morgan are acting as
joint lead book-running managers for the offering. BofA Merrill Lynch,
Barclays Capital Inc. and Piper Jaffray & Co. are acting as book-running
managers for the offering. Oddo BHF SCA, Oppenheimer & Co. Inc., Needham
& Company, LLC and Chardan are acting as co-managers for the offering.

Registration statements relating to the shares being sold in this
offering have been filed with the Securities and Exchange Commission and
were declared effective on December 6, 2018. The offering is being made
only by means of a prospectus. Copies of the final prospectus may be
obtained, when available, from Morgan Stanley & Co. LLC, Attention:
Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York
10014; from Goldman Sachs & Co. LLC, Attention: Prospectus Department,
200 West Street, New York, New York 10282, telephone: 1-866-471-2526,
facsimile: 212-902-9316, or email: prospectus-ny@ny.email.gs.com;
or from J.P. Morgan Securities LLC, Attention: Broadridge Financial
Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, telephone:
1-866- 803-9204, or email: prospectus-eq_fi@jpmchase.com.

This press release shall not constitute an offer to sell or a
solicitation of an offer to buy these securities, nor shall there be any
sale of these securities in any state or jurisdiction in which such
offer, solicitation or sale would be unlawful prior to the registration
or qualification under the securities law of any such state or
jurisdiction.

About Moderna

Moderna pioneers the discovery and development of messenger RNA (mRNA)
therapeutics and vaccines to direct the body’s cells to produce
intracellular or secreted proteins that can have a therapeutic or
preventive benefit for both patients and healthy individuals.

Contacts

Media:
Jason Glashow
Head of Corporate Communications
617-674-5648
jason.glashow@modernatx.com

Investors:
Lorence
Kim
Chief Financial Officer
617-209-5849
lorence.kim@modernatx.com